Cargando…
Continuing to Confront COPD International Patient Survey: methods, COPD prevalence, and disease burden in 2012–2013
PURPOSE: The Continuing to Confront COPD International Patient Survey aimed to estimate the prevalence and burden of COPD globally and to update findings from the Confronting COPD International Survey conducted in 1999–2000. MATERIALS AND METHODS: Chronic obstructive pulmonary disease (COPD) patient...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4057333/ https://www.ncbi.nlm.nih.gov/pubmed/24944511 http://dx.doi.org/10.2147/COPD.S61854 |
_version_ | 1782320943932112896 |
---|---|
author | Landis, Sarah H Muellerova, Hana Mannino, David M Menezes, Ana M Han, MeiLan K van der Molen, Thys Ichinose, Masakazu Aisanov, Zaurbek Oh, Yeon-Mok Davis, Kourtney J |
author_facet | Landis, Sarah H Muellerova, Hana Mannino, David M Menezes, Ana M Han, MeiLan K van der Molen, Thys Ichinose, Masakazu Aisanov, Zaurbek Oh, Yeon-Mok Davis, Kourtney J |
author_sort | Landis, Sarah H |
collection | PubMed |
description | PURPOSE: The Continuing to Confront COPD International Patient Survey aimed to estimate the prevalence and burden of COPD globally and to update findings from the Confronting COPD International Survey conducted in 1999–2000. MATERIALS AND METHODS: Chronic obstructive pulmonary disease (COPD) patients in 12 countries worldwide were identified through systematic screening of population samples. Telephone and face-to-face interviews were conducted between November 2012 and May 2013 using a structured survey that incorporated validated patient-reported outcome instruments. Eligible patients were adults aged 40 years and older who were taking regular respiratory medications or suffered with chronic respiratory symptoms and reported either 1) a physician diagnosis of COPD/emphysema, 2) a physician diagnosis of chronic bronchitis, or 3) a symptom-based definition of chronic bronchitis. The burden of COPD was measured with the COPD Assessment Test (CAT) and the modified Medical Research Council (mMRC) Dyspnea Scale. RESULTS: Of 106,876 households with at least one person aged ≥40 years, 4,343 respondents fulfilled the case definition of COPD and completed the full survey. COPD prevalence ranged from 7% to 12%, with most countries falling within the range of 7%–9%. In all countries, prevalence increased with age, and in all countries except the US was greater among men (range 6%–14%) than among women (range 5%–11%). A significant disease burden was observed when considering COPD symptoms or health status, and showed wide variations across countries. Prevalence of moderate-to-severe dyspnea (mMRC scale ≥2) ranged from 27% to 61%, and mean CAT score ranged from 16.0 to 24.8, indicating medium-to-high impairment. CONCLUSION: This survey, representing 12 countries, showed similar rates of estimated COPD prevalence across countries that were higher than those reported a decade ago in the original Confronting COPD International Survey. A significant burden of COPD was demonstrated by symptoms and health care-resource use, similar to that reported in the original survey. |
format | Online Article Text |
id | pubmed-4057333 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-40573332014-06-18 Continuing to Confront COPD International Patient Survey: methods, COPD prevalence, and disease burden in 2012–2013 Landis, Sarah H Muellerova, Hana Mannino, David M Menezes, Ana M Han, MeiLan K van der Molen, Thys Ichinose, Masakazu Aisanov, Zaurbek Oh, Yeon-Mok Davis, Kourtney J Int J Chron Obstruct Pulmon Dis Original Research PURPOSE: The Continuing to Confront COPD International Patient Survey aimed to estimate the prevalence and burden of COPD globally and to update findings from the Confronting COPD International Survey conducted in 1999–2000. MATERIALS AND METHODS: Chronic obstructive pulmonary disease (COPD) patients in 12 countries worldwide were identified through systematic screening of population samples. Telephone and face-to-face interviews were conducted between November 2012 and May 2013 using a structured survey that incorporated validated patient-reported outcome instruments. Eligible patients were adults aged 40 years and older who were taking regular respiratory medications or suffered with chronic respiratory symptoms and reported either 1) a physician diagnosis of COPD/emphysema, 2) a physician diagnosis of chronic bronchitis, or 3) a symptom-based definition of chronic bronchitis. The burden of COPD was measured with the COPD Assessment Test (CAT) and the modified Medical Research Council (mMRC) Dyspnea Scale. RESULTS: Of 106,876 households with at least one person aged ≥40 years, 4,343 respondents fulfilled the case definition of COPD and completed the full survey. COPD prevalence ranged from 7% to 12%, with most countries falling within the range of 7%–9%. In all countries, prevalence increased with age, and in all countries except the US was greater among men (range 6%–14%) than among women (range 5%–11%). A significant disease burden was observed when considering COPD symptoms or health status, and showed wide variations across countries. Prevalence of moderate-to-severe dyspnea (mMRC scale ≥2) ranged from 27% to 61%, and mean CAT score ranged from 16.0 to 24.8, indicating medium-to-high impairment. CONCLUSION: This survey, representing 12 countries, showed similar rates of estimated COPD prevalence across countries that were higher than those reported a decade ago in the original Confronting COPD International Survey. A significant burden of COPD was demonstrated by symptoms and health care-resource use, similar to that reported in the original survey. Dove Medical Press 2014-06-06 /pmc/articles/PMC4057333/ /pubmed/24944511 http://dx.doi.org/10.2147/COPD.S61854 Text en © 2014 Landis et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Original Research Landis, Sarah H Muellerova, Hana Mannino, David M Menezes, Ana M Han, MeiLan K van der Molen, Thys Ichinose, Masakazu Aisanov, Zaurbek Oh, Yeon-Mok Davis, Kourtney J Continuing to Confront COPD International Patient Survey: methods, COPD prevalence, and disease burden in 2012–2013 |
title | Continuing to Confront COPD International Patient Survey: methods, COPD prevalence, and disease burden in 2012–2013 |
title_full | Continuing to Confront COPD International Patient Survey: methods, COPD prevalence, and disease burden in 2012–2013 |
title_fullStr | Continuing to Confront COPD International Patient Survey: methods, COPD prevalence, and disease burden in 2012–2013 |
title_full_unstemmed | Continuing to Confront COPD International Patient Survey: methods, COPD prevalence, and disease burden in 2012–2013 |
title_short | Continuing to Confront COPD International Patient Survey: methods, COPD prevalence, and disease burden in 2012–2013 |
title_sort | continuing to confront copd international patient survey: methods, copd prevalence, and disease burden in 2012–2013 |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4057333/ https://www.ncbi.nlm.nih.gov/pubmed/24944511 http://dx.doi.org/10.2147/COPD.S61854 |
work_keys_str_mv | AT landissarahh continuingtoconfrontcopdinternationalpatientsurveymethodscopdprevalenceanddiseaseburdenin20122013 AT muellerovahana continuingtoconfrontcopdinternationalpatientsurveymethodscopdprevalenceanddiseaseburdenin20122013 AT manninodavidm continuingtoconfrontcopdinternationalpatientsurveymethodscopdprevalenceanddiseaseburdenin20122013 AT menezesanam continuingtoconfrontcopdinternationalpatientsurveymethodscopdprevalenceanddiseaseburdenin20122013 AT hanmeilank continuingtoconfrontcopdinternationalpatientsurveymethodscopdprevalenceanddiseaseburdenin20122013 AT vandermolenthys continuingtoconfrontcopdinternationalpatientsurveymethodscopdprevalenceanddiseaseburdenin20122013 AT ichinosemasakazu continuingtoconfrontcopdinternationalpatientsurveymethodscopdprevalenceanddiseaseburdenin20122013 AT aisanovzaurbek continuingtoconfrontcopdinternationalpatientsurveymethodscopdprevalenceanddiseaseburdenin20122013 AT ohyeonmok continuingtoconfrontcopdinternationalpatientsurveymethodscopdprevalenceanddiseaseburdenin20122013 AT daviskourtneyj continuingtoconfrontcopdinternationalpatientsurveymethodscopdprevalenceanddiseaseburdenin20122013 |